Floris Ilaria, Rose Thorsten, Rojas Juan Antonio Collado, Appel Kurt, Roesch Camille, Lejeune Beatrice
Preclinical Research, Clinical Research, Regulatory Affairs Departments, Labo'Life France, Nantes, France.
VivaCell Biotechnology GmbH, Denzlingen, Germany.
Dose Response. 2020 Oct 21;18(4):1559325820961723. doi: 10.1177/1559325820961723. eCollection 2020 Oct-Dec.
Tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) are pro-inflammatory cytokines involved in acute and chronic inflammatory diseases. Indeed, immunotherapy blocking these 2 cytokines has been developed. Micro-immunotherapy (MI) also uses ultra-low doses (ULD) of pro-inflammatory cytokines, impregnated on lactose-sucrose pillules, to counteract their overexpression. The study has been conducted with 2 objectives: examine the anti-inflammatory effect in vitro and the capacity of 2 unitary medicines, TNF-α (27 CH) and IL-1β (27 CH), to reduce the secretion of TNF-α in human primary monocytes and THP-1 cells differentiated with phorbol-12-myristate-13-acetate, after lipopolysaccharide (LPS) exposure; then, investigate the presence of particles possibly containing starting materials using tunable resistive pulse sensing technique. The results show that the unitary medicines, tested at 3 pillules concentrations (5.5, 11 and 22 mM), have reduced the secretion of TNF-α in both models by about 10-20% vs. vehicle control, depending on concentration. In this exploratory study, particles (150-1000 nm) have been detected in MI ULD-impregnated pillules and a hypothesis for MI medicines mode of action has been proposed. Conscious that more evaluations are necessary, authors are cautious in the conclusions because the findings described in the study are still limited, and future investigations may lead to different hypothesis.
肿瘤坏死因子-α(TNF-α)和白细胞介素-1β(IL-1β)是参与急慢性炎症性疾病的促炎细胞因子。事实上,已经开发出了阻断这两种细胞因子的免疫疗法。微免疫疗法(MI)还使用超低剂量(ULD)的促炎细胞因子,将其负载在乳糖-蔗糖药丸上,以对抗它们的过度表达。本研究有两个目的:在体外检测抗炎作用,以及检测两种单一药物TNF-α(27 CH)和IL-1β(27 CH)在脂多糖(LPS)刺激后,对人原代单核细胞和经佛波酯-12-肉豆蔻酸酯-13-乙酸酯分化的THP-1细胞中TNF-α分泌的降低能力;然后,使用可调电阻脉冲传感技术研究可能含有起始原料的颗粒的存在情况。结果表明,在3种药丸浓度(5.5、11和22 mM)下测试的单一药物,与载体对照相比,在两种模型中均使TNF-α的分泌降低了约10%-20%,具体取决于浓度。在这项探索性研究中,在负载了MI ULD的药丸中检测到了颗粒(150-1000 nm),并提出了MI药物作用模式的假设。作者意识到需要更多的评估,因此在结论中持谨慎态度,因为该研究中描述的发现仍然有限,未来的研究可能会得出不同假设。